Overview

Liver Safety Under Upfront Arimidex vs Tamoxifen

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases. The second objectives are to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidences of abnormal liver function test, and time to treatment failure.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Anastrozole
Tamoxifen